Infarmed, the Portuguese Medicines and Health Products Authority, has authorized the use of the medicine pembrolizumab for the treatment of metastatic triple negative breast cancer, metastatic colorectal cancer, persistent cervical cancer, metastatic oesophageal cancer, renal cell carcinoma in adults and some cases of melanoma. Read more here

ELS can and will help you develop your new medicine, carry out feasibility studies and get your product regulated. If you would like to know more, please contact your ELS local consultant or through the email:

Contact us

We will contact you as soon as possible.